Bangkok Genomics Innovation Public Company LimitedSET: BKGI🇹🇭 TH

Risk Management · 2025

Risk Management Policy & Plan

Policy & Plan Description

Risk Management Policy and Practices

1. The company is committed to becoming an organization that fosters progress for the benefit of all stakeholders, including shareholders, employees, and other relevant parties. The company places significant importance on risk management, which is a crucial element of good corporate governance

2. The company will plan, implement systems, and establish risk management processes across the organization to align with its business strategies and goals. It will operate in accordance with internationally recognized risk management standards. The risk management process must be conducted systematically and continuously, with clear communication and understanding at every stage for all employees, making risk management an integral part of the organization's work culture.

3. The Audit Committee has the authority to oversee the company's risk management and provide guidance to the Board and Risk Management Committee to ensure that risk management is conducted effectively and efficiently.

4. The Risk Management Committee is responsible for performing its duties and responsibilities, as well as carrying out tasks assigned by the Audit Committee or the Board. It must report the results of its activities to the Audit Committee. For risks that are high or critical and may significantly impact the company's operations and strategies, these must be reported to the Audit Committee, and a risk management plan must be developed with progress reports within the specified time frame.

5. Executives and all employees are required to comply with the company's risk management systems and processes. This includes identifying and assessing risks in their respective areas of responsibility, analyzing risks, impacts, and opportunities, and jointly determining appropriate measures to manage risks at an acceptable level.

6. The company will communicate its risk management policies, organize workshops, and provide training to all employees to ensure knowledge, understanding, and awareness of the benefits of risk management, enabling practical application in their work.

Risks to the Company's Business Operations

Risk Register

Risk NameRisk CharacteristicsConsequencesManagement MeasuresRelated Risk Factors
Risk of misdiagnosis

Genetic and disease screening tests help increase the likelihood of detecting abnormalities or potential health risks at an early stage. However, these tests are designed to assess risk and do not constitute definitive diagnostic confirmation of diseases or genetic abnormalities due to the limitations of current medical technologies. Examples include prenatal genetic screening, preimplantation genetic testing for aneuploidy (PGT-A), and cancer screening tests such as COLOTECT. Although these tests generally demonstrate high accuracy, false positive or false negative results may still occur. Therefore, if screening results indicate a high risk, individuals are typically advised to undergo additional diagnostic testing under a physician’s supervision to confirm the findings.

Furthermore, laboratory testing services depend on the accuracy of analytical processes, instruments, equipment, reagents, and the expertise of personnel. Errors at any stage-such as sample collection, preparation, analysis, or reporting—may lead to inaccurate results, which could affect medical decision-making and potentially impact the confidence of patients, physicians, and business partners, as well as the Company’s reputation.

If errors or inaccuracies occur in laboratory testing or limitations arise in interpreting screening results, patients or physicians may rely on incorrect information for medical decision-making, which could potentially affect patients’ health.

In addition, such incidents may undermine the confidence of patients, physicians, and business partners, and may adversely affect the Company’s image and reputation. In certain cases, they may also lead to complaints, claims for damages, or legal proceedings, which could impact the Company’s business operations and financial position.

To manage the aforementioned risks, the Company has established the following key measures:

1. Provision of Adequate Information and Informed Consent
Prior to undergoing screening services, customers are provided with clear explanations regarding the objectives, limitations, and conditions of the tests, including factors that may affect the accuracy of the results. Such information is specified in the Consent Form to ensure that customers can make well-informed decisions. In addition, certain screening services may include a test result guarantee, under which customers may receive financial support for additional diagnostic testing if a high-risk result is detected, subject to the terms and conditions of the selected service package.

2. Quality Control and Standardized Testing Procedures
The Company has established standardized operating procedures covering all stages of the laboratory process, by ISO15189:2022 and ISO15190:2020, from sample collection and preparation to analysis and reporting. The Company also utilizes standardized instruments, equipment, and reagents, and conducts regular calibration, maintenance, and both internal and external quality control to ensure the accuracy and reliability of test results.

3. Personnel Development and Service Quality Monitoring
The Company places strong emphasis on enhancing the capabilities of its personnel by providing continuous training and development in relevant scientific knowledge and technologies. In addition, the Company regularly monitors and reviews service quality to effectively manage risks and maintain appropriate standards of service.

1723 · Description: Legal risk · Info category: COMPLIANCE_RISK · 736 · Description: Damage to company image and reputation · Info category: STRATEGIC_RISK
The risk of non-compliance with laws, regulations, and other applicable rules related to the business.

The Company operates a laboratory business providing laboratory testing services and genetic disease screening; therefore, it is exposed to compliance risks related to laws, regulations, and requirements imposed by regulatory authorities. The Company’s operations require obtaining licenses from relevant authorities and strict compliance with applicable laws and standards, such as the Healthcare Facility Act B.E. 2541 (1998) and its amendments, the Medical Device Act B.E. 2551 (2008) and its amendments, and the Ministry of Public Health Notification on Standards for Genomic Medicine Services in Healthcare Facilities B.E. 2564 (2021), among others. Risks may arise from operating without the required licenses or failing to renew expired licenses, non-compliance with regulatory conditions, laboratory testing processes or quality management systems that do not meet required standards, improper management of chemicals and hazardous waste, inadequate occupational safety measures for personnel, as well as risks related to personal data protection and the accuracy of laboratory test reporting.

If the Company fails to comply with applicable laws, standards, or regulatory requirements, it may result in the suspension or cessation of its operations, revocation or suspension of its operating licenses, as well as fines or legal proceedings. In addition, the Company’s laboratory accreditation may be suspended or revoked, which could affect the reliability of test results and potentially cause damage to clients or organizations relying on such results. Non-compliance may also lead to accidents, contamination, or adverse impacts on the environment and the health and safety of laboratory personnel, as well as potential violations of clients’ personal data. Ultimately, these issues could adversely affect the Company’s reputation, credibility, and the confidence of customers and stakeholders in the long term.

The Company places importance on compliance with applicable laws, regulations, and requirements, and has established policies to manage risks related to legal and regulatory compliance as follows:

1. Governance and Monitoring of Legal and Regulatory Compliance
The Company regularly monitors and reviews relevant laws, regulations, and requirements imposed by regulatory authorities. Changes in laws and regulations are monitored through various channels, such as official websites of relevant government agencies, participation in academic conferences, and professional associations. In addition, the risk management working group is assigned to periodically review relevant laws and regulatory requirements to ensure that the Company’s operations remain in compliance.

2. Quality Control and Laboratory Operational Standards
The Company maintains quality control over its laboratory testing processes in accordance with relevant laboratory standards. This includes regular calibration and maintenance of equipment, as well as maintaining and reviewing quality management documentation to ensure the accuracy and reliability of laboratory test results.

3. Personnel Development, Safety Measures, and Data Protection
The Company emphasizes enhancing personnel knowledge and understanding of operational procedures, regulations, and applicable laws. The Company also implements safety measures for laboratory operations and establishes measures to protect clients’ personal data, in order to support business operations in compliance with applicable laws and standards.

756 · Description: Change in laws and regulations · Info category: COMPLIANCE_RISK · 757 · Description: Laws and regulations is not favorable for doing business · Info category: COMPLIANCE_RISK · 758 · Description: Violations of laws and regulations · Info category: COMPLIANCE_RISK
Business competition risks

The operation of a laboratory business providing medical and genetic testing services is exposed to increasing industry competition, driven by the entry of new market participants and rapid advancements in medical and diagnostic technologies. In addition, the growing focus on precision medicine has attracted greater interest in this sector, which may intensify competition in terms of pricing, service quality, and continuous technological development. Furthermore, the Company’s operations depend on business partners and participants within the supply chain, such as manufacturers and suppliers of medical equipment, reagents, and laboratory consumables. Any changes in pricing, supply shortages, or procurement constraints may affect the Company’s operations. Moreover, uncertainty in economic conditions may impact consumers’ purchasing power and demand for services, which could in turn affect the Company’s revenue and operating performance in the future.

If the Company is unable to adapt effectively to increasing competition, technological changes, or fluctuations in the supply chain, it may result in a loss of market share, reduced competitiveness, or higher operating costs. In addition, shortages of laboratory equipment, instruments, or reagents used in testing may affect the continuity of the Company’s services. Furthermore, uncertainty in economic conditions may reduce demand for such services, which could adversely affect the Company’s revenue, operating performance, and growth prospects in the future.

To maintain its competitiveness and respond to changes in the industry, the Company has established the following risk management measures:

1. Continuous Development of Technology and Service Capabilities
The Company closely monitors advancements in genomic medicine and laboratory testing technologies and continuously enhances its equipment, technologies, and service processes. Leveraging the innovations and technologies of the BGI Group, supported by one of the world’s largest genetic research databases, the Company is able to deliver accurate and reliable testing results. In addition, the Company performs laboratory testing within Thailand, which helps reduce turnaround time, lower transportation costs, and enhance flexibility in developing products and service packages that meet customer needs.

2. Strengthening Personnel Capabilities and Service Readiness
The Company continuously develops the capabilities of its laboratory personnel and maintains standardized laboratory systems and equipment to support the rapid development and provision of new testing services. During the outbreaks of COVID-19 and Monkeypox Virus, the Company was able to promptly provide testing services after being approved as a network laboratory and successfully passing proficiency testing by the Department of Medical Sciences. The Company also maintains readiness to support testing services for emerging infectious diseases or new virus strains in the future.

732 · Description: Changes in technologies · Info category: STRATEGIC_RISK · 733 · Description: Business operations of partners in the supply chain · Info category: STRATEGIC_RISK · 746 · Description: Delays in the development of future projects · Info category: OPERATIONAL_RISK · 1714 · Description: Competition risk · Info category: STRATEGIC_RISK · 1715 · Description: Economic risk · Info category: STRATEGIC_RISK
The risk of fluctuations in foreign exchange rates.

The Company is exposed to foreign exchange risk due to fluctuations in exchange rates. This is because most of the Company’s purchases of medical equipment, reagents, and laboratory consumables are imported from overseas and must be paid in U.S. dollars (USD), while the majority of the Company’s service revenue is denominated in Thai Baht (THB). Therefore, fluctuations in exchange rates may affect the Company’s operating costs.

If the Thai Baht (THB) depreciates against the U.S. dollar (USD), the cost of purchasing goods and equipment may increase, which could adversely affect the Company’s profit margins and operating results.

The Company closely monitors exchange rate trends and manages its purchasing and payment schedules in line with exchange rate conditions to mitigate potential impacts on its operations. In addition, the Company has a policy to utilize financial instruments for managing foreign exchange risk, such as entering into forward exchange contracts, and coordinates with financial institutions to obtain information and closely monitor exchange rate fluctuations on an ongoing basis.

730 · Description: Government policy · Info category: STRATEGIC_RISK · 764 · Description: Fluctuation in exchange rates, interest rates, or the inflation rate · Info category: FINANCIAL_RISK
Information Technology Systems and Cybersecurity Risk

The Company is exposed to risks from cyberattacks and unauthorized access to data, as its operations involve medical and genetic information, which are highly sensitive and critical. In addition, the provision of services through information systems and online platforms may increase exposure to external threats, such as system intrusion, network attacks, or data breaches.

If a data security incident occurs, it may result in the unauthorized disclosure or misuse of customer information, which could adversely affect customer confidence. The Company’s operations may be disrupted, and such incidents may also lead to financial losses, legal liabilities, and damage to the Company’s reputation and corporate image.

The Company has established comprehensive information security measures as follows:

1.Technical Measures
The Company has implemented cybersecurity prevention and detection systems, such as a Next-Generation Firewall (NGFW), to monitor and protect against both external and internal threats in real time. In addition, the Company utilizes additional website protection services to restrict access to internal systems and mitigate cyberattack risks.

2.Policy and Procedural Measures
The Company has established an Information Security Policy in accordance with international standards such as ISO 27001 and conducts regular IT risk assessments. Real-time alert systems are also in place to enable prompt response and mitigation of any abnormal incidents.

3.Personnel Measures
The Company emphasizes the development of employees’ cybersecurity awareness by providing regular training programs. It also enhances specialized skills for IT personnel to strengthen readiness in preventing and responding to potential cyber threats.

741 · Description: Systems or internal control system · Info category: OPERATIONAL_RISK · 1723 · Description: Legal risk · Info category: COMPLIANCE_RISK · 744 · Description: Information security and cyber-attack · Info category: OPERATIONAL_RISK · 736 · Description: Damage to company image and reputation · Info category: STRATEGIC_RISK · 1720 · Description: System disruption risk · Info category: OPERATIONAL_RISK

Risks to Securities Holders' Investment

Risk Register

Risk NameRisk CharacteristicsConsequencesManagement MeasuresRelated Risk Factors
The company's shareholders may face limitations in exercising their rights to purchase additional common shares in the future.

Shareholders of the Company may be subject to limitations in exercising their rights to subscribe for the Company’s securities in the future. This is because the Company may, from time to time, issue and offer additional securities, such as newly issued ordinary shares, warrants, transferable subscription rights (TSR), or convertible debentures, which may be allocated to existing shareholders in proportion to their shareholding (Rights Offering).

In this regard, in the event that such offerings or rights are granted to existing shareholders, the Company may, at its discretion, choose not to offer subscription rights to certain shareholders residing outside Thailand (Restricted Countries) if such offering would require the Company to comply with the laws or regulatory requirements of those jurisdictions. As a result, such shareholders may not be able to fully exercise their rights.

Compliance with securities laws or regulatory requirements in certain jurisdictions may result in some investors being unable to exercise their rights to subscribe for securities on a pro rata basis, which may lead to a dilution of their shareholding (Dilution Effect).

The Company carefully considers applicable legal and regulatory requirements in each jurisdiction when conducting securities offerings, and may appoint legal advisors or relevant experts to assess constraints and determine appropriate approaches. In addition, the Company will clearly and transparently disclose information regarding the terms and limitations of shareholders’ rights to enable investors to make informed decisions. The Company will also consider appropriate measures to mitigate potential impacts on shareholders within the scope permitted by applicable laws.

2970 · Description: Risk of the company having a majority shareholder holding > 25% of shares · Info category: HOLDER_RISK
Risk from Industry-Specific Factors in Genomic Medicine and Laboratory Services Affecting Investment

Investment in the Company’s securities, as a provider of laboratory and genomic medicine services, may be affected by industry-specific factors, including changes in medical and genetic testing technologies, increasing competition, reliance on imported instruments, reagents, and equipment, as well as regulatory requirements and standards related to medical services and personal data protection.

These factors may affect the Company’s competitiveness, operating costs, revenue, and overall performance, which could lead to volatility in the Company’s share price and result in investors receiving returns that may not meet their expectations.

The Company focuses on continuously developing its technology and service quality, alongside effective cost management and supply chain management. It also ensures strict compliance with relevant laws and standards, as well as accurate, transparent, and adequate disclosure of information to support investors in making informed decisions.

2970 · Description: Risk of the company having a majority shareholder holding > 25% of shares · Info category: HOLDER_RISK
Contents